Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Breast Cancer Res Treat. 2017 Nov 20;168(1):107–115. doi: 10.1007/s10549-017-4583-z

Table 3.

A. PAM50 intrinsic subtype distribution within Estrogen Receptor Positive group A. ER assessment as determined by immunohistochemistry (IHC) B. ER assessment as determined by Dextran-Coated Charcoal of ligand binding assay (DCC)

A. Estrogen Receptor Positive Subgroup (by IHC)
PAM50 intrinsic subtype Nestin negative (<1%) (n=640) Nestin positive (≥ 1%) (n=32) Total P-value
0.03
Luminal A 314 (49%) 10 (31%) 324
Luminal B 273 (42.7%) 17 (53%) 290
Her2-Enriched 51 (8%) 4 (13%) 55
Basal-like 2 (0.3%) 1 (3%) 3
Total 640 32 672
B. Estrogen Receptor Positive Subgroup (by DCC)
PAM50 intrinsic subtype Nestin negative (<1%) (n=634) Nestin positive (≥ 1%) (n=34) Total P-value
<0.001
Luminal A 309 (49%) 10 (29%) 319
Luminal B 269 (42%) 17 (50%) 286
Her2-Enriched 51 (8%) 4 (12%) 55
Basal-like 5 (1%) 3 (9%) 8
Total 634 34 666